Results 241 to 250 of about 663,024 (297)

Editorial board [PDF]

open access: yesMacedonian Veterinary Review, 2008
Macedonian Veterinary Review
doaj  

Group Agency and Egalitarian Corporate Structure: The Epistemic, Incentive, and Control Dimensions

open access: yesJournal of Applied Philosophy, EarlyView.
ABSTRACT What constitutes a good corporate agent? The article answers this question by critically applying List and Pettit's theory of group agency, which emphasizes three crucial dimensions of organizational design: epistemic quality, incentive compatibility, and control.
Chi Kwok, Chris Man‐Kong Li
wiley   +1 more source

New Approach Methodologies (NAMs) in Alternative Methods: A Comparative Cytotoxicity Analysis of Nanostructured Hydroxyapatite in Adipose Stem Cells Spheroids

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT Toxicological assessment is essential in NP approval for health and medical applications. Although 2D cell culture has been widely used, 3D models, especially spheroids, provide better predictive value for toxicological risk assessments since they replicate complex cellular interactions more accurately.
Bianca Montenegro   +5 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Oxcarbazepine (OXC) is a second‐generation antiseizure medication, effective through its active metabolite, 10‐mono‐hydroxy derivative (MHD). OXC is used as adjunctive therapy for focal‐onset and primary generalized tonic–clonic seizures, with recommended dosing based on age and body weight.
Patricia D. Maglalang   +12 more
wiley   +1 more source

Editorial: Current Issues in Governance, Economics and Finance: Toward Ecosystems

open access: yes
International Journal of Finance &Economics, EarlyView.
Fadi Alkaraan, Khaled Hussainey
wiley   +1 more source

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy